XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share-Based Payments (Tables)
 9 Months Ended
Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of allocation of share based compensation expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2024202320242023
General and administrative$272 $235 $487 $380 
Sales and marketing73 50 160 148 
Research and development5 6 17 13 
Cost of oncology services29 40 191 115 
Total stock-based compensation expense$379 $331 $855 $656 
Summary of valuation assumptions for stock options Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2024 and 2023 were as follows:
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2024202320242023
Expected term in years
6
6
6
6
Risk-free interest rates
4.49%
3.70%
3.95% - 4.49%
2.87% - 3.70%
Volatility
63.41%
61.88%
62.83% - 63.41%
 61.88% - 62.58%
Dividend yield—%—%—%—%
Summary of stock option activity
The Company’s stock options activity for the nine months ended January 31, 2024 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20231,739,336 36,331 1,775,667 $4.80 4.6$2,683,000 
Granted419,730 — 419,730 6.10 9.7
Exercised(155,449)— (155,449)2.31 
Forfeited(40,750)— (40,750)6.21   
Canceled(41,285)— (41,285)4.44 
Expired(54,166)— (54,166)12.78   
Outstanding, January 31, 20241,867,416 36,331 1,903,747 5.04 5.4$3,068,000 
Vested and expected to vest as of January 31, 20241,867,416 36,331 1,903,747 5.04 5.4$3,068,000 
Exercisable as of January 31, 20241,453,363 3,750 1,457,113 4.63 4.3$3,011,000